
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
Lightship and Castor have announced a strategic partnership to run direct-to-patient (hybrid) clinical trials at scale.
For decades, clinical trials have experienced low rates of participation relative to the distribution of a condition, which can impact the ability to access diverse patient populations and construct a representative sample. One of the main reasons for this is the high burden of participation that patients often experience. Lightship’s delivery model combined with an in-house care team will provide the patient experience in clinical trials partnering with Castor’s globally compliant Decentralized Clinical Trial and Clinical Data Management platform.
For more information, click






